What the £3,000 price actually includes

The guide cost for ChondroFiller injection at London Cartilage Clinic is £3,000 for one box — and that figure is all-inclusive. There is no itemised billing, no separate consultation invoice, and no day-of-procedure surcharge. Before committing, the patient receives a single quoted price that covers every element of the episode of care.

What that £3,000 includes:

• Initial consultation — clinical assessment and imaging review to confirm suitability and establish how many boxes are required
• Real-time ultrasound imaging on the day of the injection for precise, image-guided placement
• The ChondroFiller product itself — imported from Germany under prescription from Meidrix Biomedicals GmbH, and the single largest component of the overall cost
• The injection procedure, carried out as an outpatient appointment with no general anaesthetic and no surgical incision
• Intravenous antibiotic cover administered at the time of treatment
• A six-week follow-up appointment to review progress

The same pricing structure applies across all joints — knee, hip, shoulder, ankle, and others — so the quoted figure does not vary by anatomical site. The number of boxes needed (one, two, or three) is confirmed at the initial consultation after imaging review, not on the day of the injection itself, meaning the patient knows their total cost before the procedure is scheduled.

Why the product itself is the main cost driver

Unlike a standard corticosteroid or hyaluronic acid injection — both relatively low-cost pharmaceutical preparations — ChondroFiller is a CE-marked Class III medical device. Class III is the highest-risk classification in the EU and UK medical device framework, reserved for implants that come into sustained contact with living tissue and carry a regenerative role. Achieving and maintaining that classification requires extensive manufacturing controls, batch testing, and a regulatory pathway considerably more demanding than that for a simple injection fluid.

Each 2.3 mL unit is an acellular collagen scaffold: a precisely engineered, sterile matrix that self-gels on contact with the joint environment and recruits the patient's own progenitor cells through a process called acellular matrix-induced chondrogenesis. The bioengineering required to produce a device at that specification accounts for most of its base cost before it leaves the manufacturer.

Importation from Germany adds a further layer of expense: the device crosses borders under individual prescription, subject to UK regulatory compliance, cold-chain logistics, and customs handling at each stage. Critically, those costs are fixed per box regardless of how long the appointment takes. That is why the overall price scales with the number of boxes rather than with procedure time — a one-box and a three-box treatment require a similar clinical session; what differs is the volume of implant used, and it is the implant that determines the price.

How many boxes you need and how the total is calculated

Three price points govern the total cost, each covering a different treatment volume:

| Treatment volume | Typical indication | Price | |---|---|---| | 1 box | Single focal defect | £3,000 | | 2 boxes | Larger or two-compartment defect | £5,500 | | 3 boxes | Multi-compartment or revision presentation | £8,000 |

The per-box cost decreases modestly with volume — two boxes works out at £2,750 each, three at roughly £2,667 — but each tier is set as a fixed, all-inclusive package rather than a unit rate.

Which tier applies is a clinical determination based on defect size and joint characteristics, established through imaging review at the initial consultation. A contained, single focal defect commonly requires one box; a larger defect area or one spanning two compartments may require two or three. These are individual assessments — no fixed rule maps a particular joint or diagnosis to a particular tier, and the clinic does not adjust the box count after the procedure has begun.

Each package price is fixed at whichever tier the consultation confirms, so no additional charges arise on the day of the injection itself.

CCSD codes W3111 and W8500 explained

Private medical insurers in the UK recognise procedures through a standardised coding system called CCSD (Clinical Coding and Schedule Development). These codes classify what was done for billing and reimbursement purposes — they do not describe clinical technique in the way an operative note would.

ChondroFiller injection is billed under two codes: W3111 (cartilage regeneration with collagen scaffold), which covers the regenerative scaffold element of the treatment, and W8500, a procedural billing code whose schedule label is 'arthroscopy'. That label reflects CCSD's classification architecture rather than the clinical pathway: the current service at London Cartilage Clinic is an ultrasound-guided outpatient injection — no surgical incision, no general anaesthetic, no theatre admission. Billing codes and clinical descriptions operate in different vocabularies; W8500 here identifies the procedural component for insurer processing, not the route of delivery.

Both W3111 and W8500 appear on the fee schedules of several UK private medical insurers; approvals are most frequently reported with Bupa, Aviva, and WPA. When contacting an insurer ahead of treatment, citing both codes in correspondence helps the claims team locate the relevant policy terms. Coverage outcomes depend on individual policy wording — in some cases an insurer may meet the procedural element but not the implant cost separately — and written pre-authorisation is always required before proceeding. The codes establish how the treatment is classified; they do not guarantee reimbursement.

Private insurance: what coverage is realistic

Before booking a consultation, contact your insurer in writing — quoting both codes — and ask two specific questions: whether the procedure is covered under your policy, and whether the implant cost is treated as a separate line item. Getting a written response before any appointment is the only reliable way to establish what, if anything, your policy will meet; retrospective claims for elective procedures are rarely honoured.

ChondroFiller is not available on the NHS. The pathway is either fully self-funded or supported by a private medical insurance policy that recognises both CCSD codes. Based on guidance current to October 2025, approvals have been most frequently reported with Bupa, Aviva, and WPA — though individual policy terms vary and what applied under one policy last year may not apply under yours today. Insurer schedules change; direct written enquiry is the only current source of truth.

Partial coverage is a genuinely common outcome rather than an edge case. Some policies meet the procedural element but not the implant cost, which — as the previous sections show — is the larger portion of the overall price. A patient whose insurer covers the procedure but not the device could still face a substantial out-of-pocket contribution. Understanding this split in advance, rather than after treatment, is the practical reason to obtain written pre-authorisation rather than relying on a telephone confirmation or a general policy summary.

Where £3,000 sits in a wider treatment plan

The £3,000 single-box fee represents the entry point for patients with a straightforward focal cartilage defect — one site, one compartment, a presentation suitable for a single scaffold volume. Not every patient falls into that category, and London Cartilage Clinic offers further tiers for more complex joint conditions.

For patients with KL Grade III or IV osteoarthritis, ChondroFiller may be combined with Arthrosamid at a guide cost of £6,000. These are two distinct products working through different mechanisms: ChondroFiller is the regenerative scaffold component, recruiting the body's own progenitor cells to support tissue repair; Arthrosamid is a non-regenerative polyacrylamide hydrogel that acts on the joint environment through a separate pathway. The combination is not the same treatment at a higher dose — it is two complementary approaches applied where the clinical picture warrants both.

For complex presentations, a tri-active option combining ChondroFiller, Arthrosamid, and mesenchymal stromal cell (MSC) therapy is available at £11,000. Beyond single episodes of care, a Longitudinal Lifetime Programme incorporating annual MRI monitoring and bi-annual ChondroFiller top-up injections is also available for patients who want ongoing joint surveillance and maintenance.

Which tier — if any — is appropriate is a clinical determination made at the initial consultation after imaging review, not a decision taken in advance of seeing the joint. Patients considering any of these pathways can book an initial assessment with London Cartilage Clinic at londoncartilage.com.